within 1 month. Although the combination therapy of ganciclovir and foscarnet was started on day 125, it was also ineffective.

He developed CMV retinitis in his right eye with unilateral blurring on day 204. An ocular injection of 5 mg ganciclovir once a week was started and conducted four times. Then, retinitis of the right eye was well controlled. Otherwise, he did not have any symptoms of CMV diseases. Also, he did not have the clinical manifestations of acute or chronic graft-versus-host disease.

The in vitro analyses of the clinical isolate were conducted using his urine and peripheral blood which were collected on day 224 after transplantation as described in Materials and Methods Section. Table I shows the susceptibilities of the Towne strain and the clinical isolate to ganciclovir, cidofovir, and foscarnet determined by the plaque reduction assay. Clinical isolate was resistant to foscarnet with IC_{50} greater than 100 µg/ml, but moderately resistant to ganciclovir with IC_{50} at 4.54 µg/ml. The isolate was sensitive to cidofovir with IC_{50} at only 0.20 µg/ml, while the Towne strain was sensitive to all three antiviral agents. Therefore, the dose of ganciclovir was increased to 20 mg/kg/day. CMV antigenemia decreased gradually without any additional toxicities, but did not completely disappear. Finally, cidofovir was administered at 5 mg/kg/day three times, which resulted in the clearance of CMV antigenemia without recurrence for more than a year.

Although the number of lymphocytes, especially CD4+ and CD8+ T-cells, was strongly suppressed within 100 days after transplantation, the numbers of T-cells gradually recovered after day 100. The serum IgG level was persistently higher than 1,200 mg/dl after transplantation. The quantitation of CMV-specific cytotoxic T-cells was performed with the tetramer assay. HLA-A*2402 restricted CMV-specific cytotoxic T-cells were detected at 0.12% of CD8+ T cells on day 90 after transplantation, but not detected thereafter (Fig. 1).

Nucleotide sequences of UL54 and UL97 of the clinical isolate were compared with those of the Towne and AD169 strains. The nucleotide difference of the clinical isolate was determined by comparing the sequence difference common to both the Towne and AD169 strains. There were nucleotide differences of the clinical isolate of 49 and 46 (95 in total among 7,458 bases, 1.27%) in the UL54 and 15 and 20 (35 in total among 4,248 bases, 0.82%) in UL97 to the Towne and AD169 strains, respectively (Table IIA). The nucleotides identical to neither the Towne nor AD169 strain resulted in four and two amino acid substitution in UL54 (V11L, Q578H, S655L, and G874R) and UL97 (A140V and A594V) of the clinical isolate as shown in Table IIB. Nucleotide variations of the isolate from the Towne and AD169 were 0.3% for UL54 and 0.26% for UL97 and 28 and 7 of 35 nucleotide variations were transition and transversion, respectively. The nucleotide variation from AT to GC and GC to AT were 24 and 10 in comparison to the isolates with the Towne and AD169 strains and thus favored the shift from AT to GC. One (Q578H) of the four amino acid substitutions in UL54 has been known to be responsible for the resistance to ganciclovir and foscarnet (Fig. 2B). One (A594V) of the two amino acid substitutions in UL97 has also been reported before as being responsible for ganciclovir resistance (Fig. 2A).

TABLE I. IC_{50} (µM) of Towne and CMV Isolate to Ganciclovir, Cidofovir, and Foscarnet

	Towne	Clinical isolate
Ganciclovir	3.92 + 0.20	17.8 + 4.0
Cidofovir	0.39 + 0.18	0.72 + 0.18
Foscarnet	110 + 25	>794 (100 µg/ml)

The IC_{50} values were expressed as the mean + SEM of four independent experiments.

DISCUSSION

Preemptive therapy with ganciclovir has dramatically reduced the incidence of CMV disease after allogeneic hematopoietic stem cell transplantation. However, approximately one-fourth of patients experience an increase in positive cells by the CMV antigenemia assay (rising antigenemia) despite the use of ganciclovir [Nichols et al., 2001; Asano-Mori et al., 2005]. The use of steroid has been identified as the strongest risk factor for the development of rising antigenemia, and the in vitro antiviral susceptibility assay showed that most of the isolates were sensitive to ganciclovir. Therefore, the delayed immune recovery, not the resistant virus, might be the major cause of rising antigenemia. Transplantation from a CMV-seronegative donor might also have contributed to the delayed CMV immunity in the current patient [Nichols et al., 2001]. Nevertheless, the emergence of resistant strains is not uncommon, especially in patients who require prolonged use of antiviral agents. In hematopoietic stem cell transplant recipients, children with immunodeficiency syndromes, the use of T-cell depleted grafts, and the development of graft-versus-host disease have been reported to be risk factors for the emergence of resistant CMV strains [Eckle et al., 2000, 2002; Wolf et al., 2003]. In addition, it was reported that ganciclovir resistance emerged in two adult haploidentical hematopoietic stem cell transplant recipients after prolonged preemptive therapy [Wolf et al., 2003]. Therefore, the current patient was at very high-risk for the development of the resistant CMV strain.

The in vitro susceptibility assay showed that the clinical isolate was resistant to foscarnet, moderately resistant to ganciclovir, and fully sensitive to cidofovir. The results were compatible with the clinical course that cidofovir was far more effective than ganciclovir or foscarnet to terminate CMV antigenemia. To clarify the mechanism of resistance to ganciclovir and foscarnet, the nucleotide sequence of the UL97 and UL54 genes of the clinical isolate were determined. UL97 encodes a phosphotransferase that is required to phosphorylate ganciclovir to its triphosphate form with antiviral



Fig. 1. A clinical course of the patient performed haploidentical transplantation using in vivo alemtuzumab. The CMV antigenemia was first detected early after transplantation and preemptive antiviral treatment with standard dose of intravenous ganciclovir was initiated. Because it was not effective, we changed antiviral agents from ganciclovir to foscarnet and then to the combination therapy of ganciclovir and foscarnet. After failing the increased dose of ganciclovir, we finally administered cidofovir, which resulted in the clearance of CMV reactivation.

activity [Chou, 1999]. Therefore, the mutations in UL97, especially at codons 460, 592, 594, and 595, are closely related to the resistance to ganciclovir [Chou et al., 1995; Chou, 1999]. On the other hand, UL54 encodes DNA polymerase, the main inhibitory target of antiviral agents including ganciclovir, foscarnet, and cidofovir. Therefore, the mutations in UL54 may be involved in resistance to all of these antiviral agents. However, ganciclovir resistance due solely to UL54 is rare [Smith et al., 1997], whereas foscarnet resistance is closely related to UL54 mutations. The appearance of UL54 mutations following UL97 mutations has been shown to be a higher level of resistance to ganciclovir [Erice et al., 1997; Smith et al., 1997; Wolf et al., 2003; Hantz et al., 2005]. The clinical isolate of the current patient showed four and two amino acid differences from the reference strains (Towne and AD169) in the UL54 and UL97 regions, respectively. The UL54 mutations included Q578H mutation, that is located in the δ-region C. The Q578H mutation has not been identified in a clinical isolate but has been reported to cause 10 folds resistance to foscarnet but only twice to ganciclovir in the isolate selected after in vitro passage under drug [Mousavi-Jazi et al., 2003]. However, the high-level foscarnet resistance suggested that the other three mutations (V11L, S655L, and G874R), which were not in the conserved

TABLE II. Difference Between Towne and AD169 Versus CMV Isolate

(A) Detected mutations between Towne and AD169 versus CMV isolate

Mutation	Number	%	Common mutations with the AD169 and Towne strains	%
T to C/A to G	56	43	19	54.3
C to T/G to A	56	43	9	25.7
C to A/G to T	11	7.70	1	2.9
G to C/C to G	4	3.10	1	2.9
T to G/A to C	3	2.30	5	14.3
T to A/A to T	0	0	0	0
Total	130	99	35	100
UL54	3,729 bases	95/7458 = 1.27%	24/7458 = 0.3%	
UL97	2,124 bases	35/4248 = 0.82%	11/4248 = 0.26%	

(B) Nucleotide and amino acid substitutions between Towne and AD169 versus CMV isolate

UL54	V11L, Q578H, S655L, G874R
UL97	A140V, A594V



Fig. 2. Mutations responsible for drug resistance in the CMV gene. Many mutations responsible for drug resistance in the UL97 and UL54 genes were reported. **A**: Mutations responsible for resistance to GCV in the UL97 gene [Erice, 1999; Lurain et al., 2001; Eckle et al., 2004]. **B**: Mutations responsible for drug resistance in the UL54 gene. GCV, ganciclovir; ADV, adefovir; PFA, foscarnet; CDV, cidofovir; LBV, lobucavir.

regions of DNA polymerase among different herpesviruses, might also have affected the susceptibility to foscarnet. Mutations in the UL54 region may cause cross-resistance to all of these antiviral agents, but interestingly, the mutations in the UL54 region in this strain did not affect the susceptibility to cidofovir. Similar ganciclovir-resistant mutants with resistance to ganciclovir and foscarnet but sensitivity to cidofovir have been reported [Erice et al., 1997; Smith et al., 1997; Erice, 1999; Lurain et al., 2001; Ducancelle et al., 2004]. The UL97 mutations included A594V, that has been reported to be associated with ganciclovir resistance [Abraham et al., 1999; Erice, 1999; Gilbert et al., 2001; Lurain et al., 2001; Ducancelle et al., 2004; Eckle et al., 2004; Scott et al., 2004]. Therefore, ganciclovir resistance was mainly caused by A594V mutation in the UL97 region and probably enhanced by Q578H in the UL54 region. While the other four mutations in the UL 97 and UL54 regions might have been involved in the development of resistance, these mutations have not been reported before and further studies are required to clarify the impact of these substitutions.

In conclusion, the emergence of the resistant CMV strain was observed in a patient who had undergone haploidentical hematopoietic stem cell transplantation with in vivo T- and B-cell depletion. Profound immunosuppression as well as the prolonged use of antiviral agents might have affected the emergence of resistant strains. However, the CMV reactivation and CMV disease were successfully treated with cidofovir, selected according to the in vitro susceptibility assay. Therefore, as the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation recommended, resistance testing should be

performed for patients who failed first-line antiviral treatment allowing selection of the correct second-line antiviral therapy [Ljungman et al., 2004].

REFERENCES

Abraham B, Lastere S, Reynes J, Bibollet-Ruche F, Vidal N, Segondy M. 1999. Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates from patients with AIDS treated with ganciclovir. J Clin Virol 13:141–148.

Asano-Mori Y, Oshima K, Sakata-Yanagimoto M, Nakagawa M, Kandabashi K, Izutsu K, Hangaishi A, Motokura T, Chiba S, Kurokawa M, Hirai H, Kanda Y. 2005. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant 36:813–819.

Bainton RD, Byrne JL, Davy BJ, Russell NH. 2002. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. Blood 100:3843–3844.

Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. 1996. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 88:4063–4071.

Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S. 2002. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99:1071–1078.

Chou S. 1999. Antiviral drug resistance in human cytomegalovirus. Transpl Infect Dis 1:105–114.

Chou S, Erice A, Jordan MC, Vercellotti GM, Michels KR, Talarico CL, Stanat SC, Biron KK. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 171:576–583.

Cockley KD, Shiraki K, Rapp F. 1988. A human cytomegalovirus function inhibits replication of herpes simplex virus. J Virol 62: 188–195.

Ducancelle A, Belloc S, Alain S, Scieux C, Malphettes M, Petit F, Brouet JC, Sanson Le Pors MJ, Mazeron MC. 2004. Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy. J Clin Virol 29:241–247.

Eckle T, Prix L, Jahn G, Klingebiel T, Handgretinger R, Selle B, Hamprecht K. 2000. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 96:3286–3289.

Eckle T, Lang P, Prix L, Jahn G, Klingebiel T, Handgretinger R, Selle B, Niethammer D, Hamprecht K. 2002. Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. Bone Marrow Transplant 30:433–439.

Eckle T, Jahn G, Hamprecht K. 2004. The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay. J Clin Virol 30:50–56.

Erice A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 12:286–297.

Erice A, Gil-Roda C, Perez JL, Balfour HH, Jr., Sannerud KJ, Hanson MN, Boivin G, Chou S. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 175:1087–1092.

Gilbert C, Roy J, Belanger R, Delage R, Beliveau C, Demers C, Boivin G. 2001. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob Agents Chemother 45:3669–3671.

Gilleece MH, Dexter TM. 1993. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82:807–812.

Hantz S, Michel D, Fillet AM, Guigonis V, Champier G, Mazeron MC, Bensman A, Denis F, Mertens T, Dehee A, Alain S. 2005. Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient. Antimicrob Agents Chemother 49:1580–1583.

Ida M, Kageyama S, Sato H, Kamiyama T, Yamamura J, Kurokawa M, Morohashi M, Shiraki K. 1999. Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir resistant variants. Antiviral Res 40:155–166.

Kanda Y, Mineishi S, Nakai K, Saito T, Tanosaki R, Takaue Y. 2001a. Frequent detection of rising cytomegalovirus antigenemia after allogeneic stem cell transplantation following a regimen containing antithymocyte globulin. Blood 97:3676–3677.

Kanda Y, Mineishi S, Saito T, Seo S, Saito A, Suenaga K, Ohnishi M, Niiya H, Nakai K, Takeuchi T, Kawahigashi N, Shoji N, Ogasawara T, Tanosaki R, Kobayashi Y, Tobinai K, Kami M, Mori S, Suzuki R, Kunitoh H, Takaue Y. 2001b. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: A single-center experience in Japan. Bone Marrow Transplant 27:437–444.

Kanda Y, Mineishi S, Saito T, Saito A, Ohnishi M, Niiya H, Chizuka A, Nakai K, Takeuchi T, Matsubara H, Makimoto A, Tanosaki R, Kunitoh H, Tobinai K, Takaue Y. 2002. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: A prospective evaluation. Transplantation 73:568–572.

Kanda Y, Oshima K, Asano-Mori Y, Kandabashi K, Nakagawa M, Sakata-Yanagimoto M, Izutsu K, Hangaishi A, Tsujino S, Ogawa S, Motokura T, Chiba S, Hirai H. 2005. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 79:1351–1357.

Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S. 2000. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96: 2419–2425.

Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiusolo P, Tarnani M, Fadda G, Sica S, Leone G. 2004. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: Incidence and treatment with oral ganciclovir. Haematologica 89:1248–1252.

Ljungman P, Reusser P, de la Camara R, Einsele H, Engelhard D, Ribaud P, Ward K. 2004. Management of CMV infections: Recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 33:1075–1081.

Lurain NS, Weinberg A, Crumpacker CS, Chou S. 2001. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob Agents Chemother 45:2775–2780.

Mousavi-Jazi M, Schloss L, Wahren B, Brytting M. 2003. Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase. J Clin Virol 26:301–306.

Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, Coutre SE. 2002. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 3:105–110.

Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M, Davis C, Boeckh M. 2001. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes. Blood 97:867–874.

Scott GM, Isaacs MA, Zeng F, Kesson AM, Rawlinson WD. 2004. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. J Med Virol 74:85–93.

Shiraki K, Ishibashi M, Okuno T, Kokado Y, Takahara S, Yamanishi K, Sonoda T, Takahashi M. 1990. Effects of cyclosporine, azathioprine, mizoribine, and prednisolone on replication of human cytomegalovirus. Transplant Proc 22:1682–1685.

Shiraki K, Ishibashi M, Okuno T, Hayashi K, Yamanishi K, Takahashi M, Ogino S, Sonoda T. 1991a. Effect of FK-506 on replication of human cytomegalovirus in vitro. J Antibiot (Tokyo) 44:550–552.

Shiraki K, Ishibashi M, Okuno T, Namazue J, Yamanishi K, Sonoda T, Takahashi M. 1991b. Immunosuppressive dose of azathioprine inhibits replication of human cytomegalovirus in vitro. Arch Virol 117:165–171.

Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 176:69–77.

Wolf DG, Lurain NS, Zuckerman T, Hoffman R, Satinger J, Honigman A, Saleh N, Robert ES, Rowe JM, Kra-Oz Z. 2003. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 101:463–465.

Yoshida Y, Li Z, Kurokawa M, Kawana T, Imakita M, Shiraki K. 2005. Growth of herpes simplex virus in epidermal keratinocytes determines cultaneous pathogenicity in mice. J Med Virol 75:421–426.

Yukawa TA, Kurokawa M, Sato H, Yoshida Y, Kageyama S, Hasegawa T, Namba T, Imakita M, Hozumi T, Shiraki K. 1996. Prophylactic treatment of cytomegalovirus infection with traditional herbs. Antivir Res 32:63–70.

European Journal of Haematology ISSN 0902-4441

ORIGINAL ARTICLE

CD16$^+$ CD56$^-$ NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft-versus-leukemia effect

Xuzhang Lu[1], Yukio Kondo[1], Hiroyuki Takamatsu[1], Kinya Ohata[1], Hirohito Yamazaki[2], Akiyoshi Takami[3], Yoshiki Akatsuka[4], Shinji Nakao[1]

[1]Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan; [2]The Protected Environmental Unit, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; [3]Division of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; [4]Division of Immunology, Aichi Cancer Research Institute, Nagoya, Aichi, Japan

Abstract

A marked increase in CD16$^+$ CD56$^-$ NK cells in the peripheral blood (PB) was observed in a cord blood transplant (CBT) recipient with refractory acute myeloid leukaemia (AML) in association with attaining molecular remission. CD16$^+$ CD56$^-$ NK cells isolated from the patient became CD16$^+$CD56$^+$NKG2D$^+$ when they were cultured in the presence of IL-2. Although cultured CD16$^+$CD56$^-$ NK cells retained the killer-cell immunoglobulin receptor (KIR)-ligand (KIR-L) specificity and the patient's leukemic cells expressed corresponding KIR ligands, they killed patient's leukemic cells expressing ULBP2. The cytotoxicity by cultured CD16$^+$CD56$^-$ NK cells was abrogated by anti-ULBP2 antibodies. When leukemic cells obtained at relapse after CBT were examined, both the ULBP2 expression and susceptibility to the cultured NK cells decreased in comparison to leukemic cells obtained before CBT. An increase in the CD16$^+$CD56$^-$ NK cell count (0.5×10^9/L or more) in PB was observed in seven of 11 (64%) CBT recipients but in none of 13 bone marrow (BM) and eight peripheral blood stem cell (PBSC) transplant recipients examined during the similar period after transplantation. These findings suggest an increase in CD16$^+$CD56$^-$ NK cells to be a phenomenon unique to CBT recipients and that mature NK cells derived from this NK cell subset may contribute to the killing of leukemic cells expressing NKG2D ligands *in vivo*.

Key words CD56$^+$CD16$^-$ NK cell; NKG2D; graft-versus-leukemia; cord blood transplantation

Correspondence Shinji Nakao, Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Kanazawa University Hospital, 13-1 Takara-machi Kanazawa, Ishikawa 920-8640, Japan. Tel: +81-76-265-2274; Fax: +81-76-234-4252; e-mail: snakao@med3.m.kanazawa-u.ac.jp

Accepted for publication 6 March 2008

doi:10.1111/j.1600-0609.2008.01073.x

Cord blood transplantation (CBT) is being increasingly used for treatment of hematologic malignancies because its efficacy in the treatment of adult patients has been proven based on the findings of recent studies (1–4). One possible drawback of CBT is the less potent graft-versus-leukemia (GVL) effect than that of bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT) due to the immaturity of T cells contained in the cord blood (CB) graft (5). However, a recent study has shown the relapse rate after CBT to be comparable to that after BMT or PBSCT from human leukocyte antigen (HLA) matched sibling donors (1). Moreover, an analysis on the outcome of CBT for adult patients with acute myeloid leukaemia (AML) in Japan revealed that the rate of leukemic relapse after HLA-mismatched CBT was lower than that after HLA-matched CBT despite the fact that the incidence of graft-versus-host disease (GVHD) was similar between the two groups (Cord Blood Bank Network of Japan; unpublished observation). These clinical findings suggest that immunocompetent cells other than T cells may mediate the GVL effect after CBT.

Natural killer (NK) cells play a major role in the development of GVL effect after an HLA-mismatched stem cell transplantation (SCT) (6, 7). The GVL effect by NK cells depends on the presence of

© 2008 Kanazawa University

HLA-mismatches and T cell recovery after SCT (8). Because CBT is often carried out from HLA-mismatched donors and is also associated with delayed T cell recovery (9–11), NK cells may be more likely to contribute to the development of GVL effect after CBT than after BMT or PBSCT. Few studies, however, have previously focused on the GVL effect by NK cells after CBT.

CB has a unique subset of NK cells characterized by a phenotype $CD16^+CD56^-$ (12–14). This NK cell subset is thought to be immature NK cells capable of differentiating into $CD16^+CD56^+$ NK cells (15). We recently observed an apparent increase in this NK cell subset in a patient who underwent reduced-intensity CBT for the treatment of relapsed AML after PBSCT from an HLA-compatible sibling donor. The patient achieved a molecular remission of AML in association with the NK cell increase. This observation prompted the characterization of $CD16^+CD56^-$ NK cells of this patient and other patients after allogeneic SCT. The present study revealed that $CD16^+CD56^-$ NK cells may potentially play a role in the development of the GVL effect in patients whose leukemic cells express NKG2D ligands.

Materials and methods

Patients

Peripheral blood (PB) was obtained from 11 CBT, 13 BMT (10 from related and three from unrelated donors), and eight PBSCT patients 2–135 months after transplantation. None of the patients had active graft-versus-host disease requiring corticosteroids at time of sampling or signs of infection. The original diseases of the CBT recipients included AML in four, non-Hodgkin's lymphoma (NHL) in four, myelodysplastic syndromes (MDS) in two and renal cell carcinoma in one. In the BMT recipients, those were AML in four, acute lymphoblastic leukemia (ALL) in four, MDS in three, chronic myeloid leukaemia (CML) in one, and aplastic anaemia (AA) in one while in the PBSCT recipients, those were AML in four, ALL in one, biphenotypic leukemia in two and NHL in one. All CBT recipients received an HLA-mismatched graft; the number of HLA mismatches between donor and recipient were two in seven, three in three and four in one. No HLA mismatch was observed between each donor and the BMT or PBSCT recipient except for six PBSCT recipients whose mismatches with their donors was one in two, two in one and three in one. This study was approved by our institutional review board and all patients gave their informed consent for the phenotypic and functional analyses of their peripheral blood mononuclear cells (PBMCs).

Phenotype analysis of PBMC after SCT and leukemia cells

The cell surface phenotype was determined by three-color flow cytometry. The cells were stained with various monoclonal antibodies (mAbs) specific to cell surface proteins including CD3, CD56, CD16, CD158a, CD158b (Becton Dickinson Pharmingen), NKG2A, NKG2D, NKp30, NKp44 and NKp46 (Beckman Coulter, Marseille, France). The expression of NKG2D ligands on leukemic cells from a CBT recipient was determined using mAbs specific to MICA/B (Becton Dickinson Pharmingen), ULBP1, ULBP2 and ULBP3 (R&D Systems, Minneapolis, MN).

Cell separation

PBMCs were isolated using density gradient centrifugation. NK cells were enriched by negative selection using immunomagnetic beads (Dynal NK cell isolation kit; Dynal Biotech, Lake success, NY) according to the manufacturer's recommendation (16). NK cell purity was confirmed by flow cytometry. $CD16^+CD56^+$ and $CD16^+CD56^-$ NK cells were separated from the enriched NK cells with anti-CD56-coated microBeads (MACS) by passing them through two sequential large-scale columns (Milteny Biotec, Gladbach, Germany) according to the manufacturer's instructions. $CD158b^+$ and $CD158b^-$ NK cells were separated with anti-CD158b-FITC Abs and anti-FITC microbeads.

NK cell culture

Isolated 2×10^6 $CD16^+CD56^+$ and $CD16^+CD56^-$ subsets were cultured with or without 2×10^5 irradiated (45 Gy) K562 cells transfected with the membrane-bound form of IL-15 and human 4-1BBL (K562-mb15-41BBL) kindly provided by Dr. Dario Campana of University of Tennessee College of Medicine (17) in RPMI1640 containing 10% fetal bovine serum (FBS), 50 U/mL penicillin, 50 μg/mL streptomycin and 100 IU/mL IL-2 for 14 d. The cultured NK cells were washed with RPMI1640 and then were used for the cytotoxicity assay.

Transfection of 721-221 cells with retroviral vector

An HLA class I-negative B cell line 721–221 was transfected with retrovirus vectors containing HLA-C*0301 (.221-Cw3) or HLA-C*0401 (.221-Cw4) as described previously (18). Transfectants were selected in the presence of 0.1 mg/mL neomycin and 0.1 mg/mL puromycin. The surface expression of HLA-C molecules was confirmed by flow cytometry using a mAb HLA-ABC (Immunotech, Marseille, France). A clone exhibiting the highest

© 2008 Kanazawa University

level of HLA-C expression was used as a target in the cytotoxicity assay.

Cytotoxicity assay

NK cell cytotoxicity was assessed using the standard chromium release assay, as described previously (19). In blocking experiments, anti-ULBP Abs were added at 10 μg/mL to the ^{51}Cr labeled target cells and target cells were incubated at 37°C for 30 min before the addition of NK cells. The percentage of specific lysis was calculated using the formula: 100 × (count per minute [cpm] released from test sample-cpm spontaneous release)/(cpm maximum release − cpm spontaneous release).

Statistical analysis

The significance of difference in the PB CD16⁺CD56⁻ cell count between CBT recipients and recipients of BM, PBSCT, or healthy individual was assessed by Student's *t*-test. The significance of difference in the time of sampling after SCT between CBT, BMT and PBSCT was assessed by Mann-Whitney test. *P*-values < 0.05 were considered to be significant.

Results

An increase in the number of CD16⁺CD56⁻ NK cells in a CBT recipient

A 56-yr-old male (Patient 1) who relapsed with AML M0 after PBSCT from a sibling donor underwent CBT following preconditioning with fludarabin 125 mg/m², melphalan 80 mg/m², and 4 Gy TBI. The patient's leukemia was refractory to chemotherapy and there were 18% leukemic blasts in the PB at the time of preconditioning. He achieved complete chimerism in PB on day 22 after CBT. The WT1 copy number in BM RNA decreased from 13 000 copies/μg RNA before the start of preconditioning to 140 copies/μg RNA on day 60 (20). However, it rose to 1500 copies/μg RNA on day 80 after CBT. Although a molecular relapse was suspected, the WT1 copy number spontaneously decreased to 230 on day 172. Surface phenotype analysis of PB leukocytes on day 84 showed an increase in the count of CD3⁻CD16⁺CD56⁻ NK cells (Fig. 1). The CD16⁺CD56⁻ NK cell count remained as high as $3.2–4.5 \times 10^9/L$ for the following 11 months during which he remained in remission. The patient eventually relapsed with AML and died 16 months after CBT. The unexpected long term remission after reduced-intensity CBT associated with an increase in the CD16⁺CD56⁻ NK cell count prompted the characterization of the CD16⁺CD56⁻ NK cells of this patient and other patients who underwent allogeneic SCT.



Figure 1 Phenotype of the CD16⁺ NK cells in the peripheral blood. Representative results of flow cytometry on CD3⁻ lymphocytes from SCT recipients and healthy individuals are shown. Gates were set up to exclude any CD3⁺ lymphocytes as shown in (A) and (B); (C) a healthy individual; (D) a CBT recipient (Patient 1); (E) a BMT recipient; (F) a PBSCT recipient.

CD16⁺CD56⁻ NK cells in PB of allogeneic SCT recipients

Because the presence of CD16⁺CD56⁻ NK cells has been reported to be characteristics of CB, the proportion of PB CD16⁺CD56⁻ NK cells as well as their absolute count was determined for other recipients of CB and the other stem cell grafts. An increase in the CD16⁺CD56⁻ NK cell count greater than $0.5 \times 10^9/L$ was seen in seven of 11 CBT recipients but in none of 13 BMT and eight PBSCT recipients (Figs 1 and 2). There was no significant difference in the time of sampling after SCT between CBT recipients and BMT recipients ($P > 0.772$) or CBT recipients and PBSCT recipients ($P > 0.265$). Both the CD16⁺CD56⁻ NK cell proportion and the absolute count were significantly higher in CBT recipients than in other SCT recipients or in healthy individuals. In contrast, there were no significant differences in the count of other NK cell subsets including $CD56^{dim}CD16^{+}$ and $CD56^{bright}CD16^{-}$ cells among these three SCT recipient groups (data not shown). A CD16⁺CD56⁻ NK cell increase greater than $1.5 \times 10^9/L$ was restricted to Patient 1 and another CBT recipient with NHL (Patient 2). The CD16⁺CD56⁻ NK cell counts of Patient 2, 5 months and 15 months after CBT were $1.5 \times 10^9/L$ and $1.8 \times 10^9/L$, respectively.

Surface phenotype of CD16⁺CD56⁻ NK cells and leukemic cells

To characterize this unusual NK cell subset, the surface phenotype was compared between CD16⁺CD56⁻ and CD16⁺CD56⁺ NK cells from Patient 1 and Patient 2

© 2008 Kanazawa University



Figure 2 The proportion (A) and the absolute count (B) of $CD3^-CD16^+CD56^-$ in the PB of SCT recipients and healthy individuals. An increase in the proportion of $CD3^-CD16^+CD56^-$ NK cells (20% or more) in the PB $CD16^+$ NK cells and an increase in the absolute count of the same NK cell subset ($>0.5 \times 10^9$/L) were observed in seven of 11 CBT recipients, but in none of allogeneic 13 BM and eight PBSC transplant recipients. The $CD3^-CD16^+CD56^-$ cell count was calculated by multiplying the WBC count with the proportion (%) of this subset among the total cell event.

(Table 1). All $CD16^+CD56^-$ cells, similarly to $CD16^+CD56^+$ cells, expressed CD11a, CD18, but did not express a B-cell marker CD19, or the myeloid marker CD33 (data not shown). There were no differences in the expression levels of two major inhibitory NK receptors CD158a and CD158b between the two NK cell subsets (data not shown). On the other hand, the proportions of cells expressing activating NK receptors including NKG2D in $CD16^+CD56^-$ NK cells tended to be lower than those of $CD16^+CD56^+$ NK cells.

The leukemic cells obtained from Patient 1 before CBT exhibited an NKG2D ligand ULBP2 (Fig. 3). When the leukemic cells obtained after relapse was examined, the ULBP2 expression was observed to have decreased to levels comparable to ULBP1 and ULBP3.

Phenotypic change of $CD16^+CD56^-$ NK cells after *in vitro* culture

$CD16^+CD56^-$ NK cells derived from CB are reported to undergo differentiation *in vitro* in the presence of IL-2 (15, 21) and are therefore thought to be precursors of $CD16^+CD56^+$ NK cells (15). $CD16^+CD56^-$ NK cells were enriched from PBMCs of Patient 1 and Patient 2 and cultured in the presence of 100 IU/ml of IL-2 with or without irradiated K562-mb15-41BBL. In accordance with the results of previous studies, $CD16^+CD56^-$ NK cells from Patient 1 became $CD16^+CD56^+$ after *in vitro* culture (Fig. 4). Cultured $CD16^+CD56^-$ NK showed a tendency toward an increased expression of activating receptors including NKp30, NKp44, NKp46 and NKG2D, but did not show any changes in the expression of inhibitory receptors including CD158a, CD158b and NKG2A (Table 1).

Specificity of cultured $CD16^+CD56^-$ NK cells

Although attaining molecular remission in association with an increase in the $CD16^+CD56^-$ NK cells suggests the involvement of these NK cells in the GVL effect,

Table 1 Phenotype of the NK cell subsets from two CBT recipients

			NKp30		NKp44		NKp46		NKG2D	
			%	MFI	%	MFI	%	MFI	%	MFI
Patient 1	$CD56^+CD16^+$	Fresh	3.7	11.5	0	7.51	56.7	37.9	61.0	35.6
		Cultured	43.1	33.2	71.2	88.9	61.3	48.1	100.0	156.0
	$CD56^+CD16^-$	Fresh	0.0	8.37	0.0	7.57	17.6	12.6	46.7	12.6
		Cultured	14.2	10.4	51.4	31.0	54.2	26.8	99.9	26.8
Patient 2	$CD56^+CD16^+$	Fresh	3.6	6.71	0.0	7.72	42.9	44.3	72.3	44.3
		Cultured	14.2	39.4	51.4	49.4	54.2	54.4	99.5	54.4
	$CD56^+CD16^-$	Fresh	0.0	8.65	0.0	8.31	21.5	16.9	69.0	16.9
		Cultured	58.1	47.6	66.3	51.4	75.2	64.8	98.5	64.8

$CD16^+CD56^-$ and $CD16^+CD56^-$ NK cells were isolated from two CBT recipients and cultured with irradiated K562-mb15-41BBL in the presence of IL-2 for 14 d. Cultured NK showed increased expression of activating NK receptors including NKp30, NKp44, NKp46 and NKG2D.

© 2008 Kanazawa University



Figure 3 Expression of NKG2D ligands on leukemic cells from Patient 1. (A) leukemic cells obtained before CBT; (B) leukemic cells obtained after relapse. The proportion of ULBP2 expressing leukemic cells decreased from 59% to 9%.



Figure 4 Phenotypic change of $CD16^+CD56^-$ NK cells with time associated with *in vitro* culture. Isolated $CD16^+CD56^-$ cells from Patient 1 were cultured in the presence of 100 IU/L IL-2 without (A) or with K562-mb15-41BBL (B). $CD16^+CD56^-$ NK cells from CBT recipients became $CD16^+CD56^+$ after the *in vitro* culture.

there was no killer-cell immunoglobulin receptor (KIR)-ligand (KIR-L) mismatch between Patient 1 and the CB donor; Patient 1 and the CB donor shared C*0102 and C*0304. To determine whether cultured NK cells derived from $CD16^+CD56^-$ NK cells retain specificity restricted by KIR-L of target cells, cultured NK cells from Patient 1 and Patient 2 who possessed C*0102 and C*1202 were separated into $CD158b^+$ and $CD158b^-$ NK cells, and were examined for their cytotoxicity against 721–221 cells transfected with different HLA-C alleles (Fig. 5). $CD158b^+$ NK cells failed to kill 721–221 cells transfected with HLA-C*0301 (.221-Cw3) while they killed both wild-type 721–221 cells and 721–221 cells transfected with HLA-C*0401 (.221-Cw4). Conversely, $CD158b^-$ NK cells not only killed 721–221 cells but they also killed .221-Cw3 and .221-Cw4 cells, thus indicating that the cytotoxicity due to the cultured $CD158b^+$ NK cells is inhibited by the KIR-L Cw3 of the target cells.

Cytotoxicity of cultured $CD16^+CD56^-$ NK cells against leukemic cells

When leukemic cells obtained from Patient 1 before CBT were used as a target, both $CD158b^+$ and $CD158b^-$ NK cells showed similar cytotoxicity to that of unfractionated NK cells (Fig. 6). The cytotoxicity was blocked by



Figure 5 Specificity of NK cells derived from $CD16^+CD56^-$ NK cells. Cultured NK cells derived from $CD16^+CD56^-$ cells of Patient 1 (A and B) and Patient 2 (C and D) were separated into $CD158b^+$ (A and C) and $CD158b^-$ cells (B and D) and were examined for the cytotoxicity against 721-221 cells and 721-221 transfected with different HLA-C alleles C*0301 (.221-Cw3) and C*0401 (.221-Cw4). The data represent one of two experiments which produced similar results.

© 2008 Kanazawa University



Figure 6 Cytotoxicity of cultured NK cells against leukemic cells. (A) Unseparated and separated NK cells were tested against leukemic cells obtained before CBT; (B) Leukemic cells were incubated in the presence of anti-ULBP1 or ULBP2 Abs before incubation with cultured NK cells; (C) Cytotoxicity of unseparated NK cells were tested against leukemic cells obtained before CBT or after relapse. The data represent one of three experiments which produced similar results.

treatment of leukemia cells with anti-ULPB2 mAbs. Leukemic cells obtained after relapse were relatively resistant to killing by cultured NK cells in comparison to those obtained before CBT.

Discussion

The present study revealed an increase in a unique NK cell subset characterized by $CD16^+CD56^-$ in CBT recipients. Although $CD3^-CD16^+CD56^-$ cells comprise monocytes, an increase in this subset was due to an increase in immature NK cells because they did not express a myeloid marker CD33 and acquired CD56 expression by *in vitro* culture in the presence of IL-2. An increase in NK cells with a similar phenotype has been shown in patients with solid tumors who were treated with IL-2 (21) and in those with HIV infection (22). Our CBT recipients did not receive cytokine therapy nor show any signs of viral infections at sampling. The expression of KIRs including CD158a and CD158b was not depressed in $CD16^+CD56^-$ cells of Patient 1 and Patient 2 in contrast to those of HIV patients (22). An *in vitro* culture of $CD16^+CD56^-$ NK cells from patients with HIV viremia in the presence IL-2 reportedly failed to induce NKp44 expression while it did induce the NKp44 expression by $CD16^+CD56^-$ NK cells from the two CBT recipients. It is therefore unlikely that the increase in the $CD16^+CD56^-$ cell count in the CBT recipients was secondary to viral infections.

Gaddy *et al.* demonstrated a novel subset of NK cells characterized by a phenotype $CD16^+CD56^-$ to exist in CB (12). They hypothesized that this NK cell subset represents immature NK cells capable of differentiating into $CD16^+CD56^+$ NK cells (15). $CD16^+CD56^-$ cells of our patients also underwent differentiation into $CD16^+CD56^+$ cells when they were cultured in the presence of IL-2. Therefore, $CD16^+CD56^-$ cells in PB after CBT may be derived from immature NK cells or NK precursor cells which existed in CB grafts. Previous studies on NK cells from SCT recipients and *ex vivo* engineered CB NK cells did not reveal an increased proportion of $CD16^+CD56^-$ cells (23–25). Both Patient 1 and Patient 2 received an HLA-mismatched CB graft although there was no KIR-L mismatch. Notably, Patient 1 had a large leukemic burden at the time of reduced-intensity preconditioning. It is therefore plausible that residual leukemic cells may have stimulated NK cell precursors to recruit $CD16^+CD56^-$ NK cells in Patient 1.

Patient 1's leukemic cells obtained before CBT expressed ULBP2. The incubation of $CD16^+CD56^-$ NK cells derived from Patient 1 in the presence of IL-2 and the K562 transfectant augmented NKG2D expression and the cultured NK cells showed cytotoxicity against leukemic cells despite that cultured NK cells retained KIR-L specificity and Patient 1's leukemic cells expressed matched KIR-L HLA-C*0304/C*0102. The cytotoxicity by the cultured NK cells decreased against leukemic cells treated with anti-ULBP2 Abs, and also against the leukemic cells obtained from Patient 1 after relapse which were devoid of ULBP2 expression. These findings suggest that mature NK cells derived from $CD16^+CD56^-$ NK cells may have exerted GVL effect on Patient 1's leukemic cells by way of interaction of NKG2D and ULBP2. The aberrant expression of NKG2D ligands by leukemic cells has been demonstrated by previous studies (26), but its influence on the outcome of allogeneic SCT has not yet been clarified. The results of the present study

© 2008 Kanazawa University

indicate that the susceptibility of leukemic cells to NK cells may depend on both expression of NKG2D ligand on leukemic cells and the expression of NKG2D on effector NK cells. In patients with acute leukemia, leukemic cells are reported to downregulate NKp30 of autologous NK cells, thereby allowing NK cells to escape leukemic cells (27, 28). In the setting of CBT, leukemic cells expressing NKG2D ligands may tend to stimulate NK cell precursors in CB, thus inducing them to undergo differentiation.

The present study demonstrated the expansion of $CD16^+CD56^-$ NK cells in the PB of CBT recipients for the first time. These immature NK cells can be expanded *ex vivo* with a help of K562-mb15-41BBL cells as maintaining specificity to KIR-L and cytotoxicity against leukemic cells expressing an NKG2D ligand. Therefore, CB may be a potential source of NK cells which can be utilized for cell therapy. Further studies on a larger number of CBT recipients are needed to determine whether $CD16^+CD56^-$ NK cells indeed play a role in the GVL effect.

Acknowledgement

We thank Dr. Dario Campana and Dr Chihaya Imai for providing us with K562-mb15-41BBL cells.

References

1. Takahashi S, Ooi J, Tomonari A, *et al.* Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. *Blood* 2007;**109**:1322–30.
2. Arcese W, Rocha V, Labopin M, *et al.* Unrelated cord blood transplants in adults with hematologic malignancies. *Haematologica* 2006;**91**:223–30.
3. Rocha V, Cornish J, Sievers EL, *et al.* Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. *Blood* 2001;**97**:2962–71.
4. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, Verfaillie CM, Wagner JE. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. *Blood* 2005;**105**:1343–7.
5. Harris DT, Schumacher MJ, Locascio J, Besencon FJ, Olson GB, DeLuca D, Shenker L, Bard J, Boyse EA. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. *Proc Natl Acad Sci U S A* 1992;**89**:10006–10.
6. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. *Blood* 1999;**94**:333–9.
7. Ruggeri L, Capanni M, Urbani E, *et al.* Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science* 2002;**295**:2097–100.
8. Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ, Miller JS. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. *Blood* 2005;**106**:4370–6.
9. Komanduri KV, St John LS, de Lima M, *et al.* Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T cell skewing. *Blood* 2007;**110**:4543–51.
10. Giraud P, Thuret I, Reviron D, Chambost H, Brunet C, Novakovitch G, Farnarier C, Michel G. Immune reconstitution and outcome after unrelated cord blood transplantation: a single paediatric institution experience. *Bone Marrow Transplant* 2000;**25**:53–7.
11. Locatelli F, Maccario R, Comoli P, *et al.* Hematopoietic and immune recovery after transplantation of cord blood progenitor cells in children. *Bone Marrow Transplant* 1996;**18**:1095–101.
12. Gaddy J, Risdon G, Broxmeyer HE. Cord blood natural killer cells are functionally and phenotypically immature but readily respond to interleukin-2 and interleukin-12. *J Interferon Cytokine Res* 1995;**15**:527–36.
13. Bradstock KF, Luxford C, Grimsley PG. Functional and phenotypic assessment of neonatal human leucocytes expressing natural killer cell-associated antigens. *Immunol Cell Biol* 1993;**71**:535–42.
14. Phillips JH, Hori T, Nagler A, Bhat N, Spits H, Lanier LL. Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 epsilon,delta proteins. *J Exp Med* 1992;**175**:1055–66.
15. Gaddy J, Broxmeyer HE. Cord blood $CD16^+56^-$ cells with low lytic activity are possible precursors of mature natural killer cells. *Cell Immunol* 1997;**180**:132–42.
16. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. *Blood* 2004;**104**:170–7.
17. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. *Blood* 2005;**106**:376–83.
18. Kondo E, Topp MS, Kiem HP, Obata Y, Morishima Y, Kuzushima K, Tanimoto M, Harada M, Takahashi T, Akatsuka Y. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. *J Immunol* 2002;**169**:2164–71.
19. Nakao S, Takami A, Takamatsu H, *et al.* Isolation of a T-cell clone showing HLA-DRB1*0405-restricted

© 2008 Kanazawa University

cytotoxicity for hematopoietic cells in a patient with aplastic anemia. *Blood* 1997;**89**:3691–9.

20. Ogawa H, Tamaki H, Ikegame K, *et al.* The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. *Blood* 2003;**101**:1698–704.
21. McKenzie RS, Simms PE, Helfrich BA, Fisher RI, Ellis TM. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2. *Cancer Res* 1992;**52**:6318–22.
22. Mavilio D, Lombardo G, Benjamin J, *et al.* Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. *Proc Natl Acad Sci U S A* 2005;**102**:2886–91.
23. Jacobs R, Stoll M, Stratmann G, Leo R, Link H, Schmidt RE. CD16- CD56+ natural killer cells after bone marrow transplantation. *Blood* 1992;**79**:3239–44.
24. Ayello J, van de Ven C, Fortino W, *et al.* Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. *Biol Blood Marrow Transplant* 2006;**12**:608–22.
25. Moretta A, Maccario R, Fagioli F, *et al.* Analysis of immune reconstitution in children undergoing cord blood transplantation. *Exp Hematol* 2001;**29**:371–9.
26. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. *Blood* 2003;**102**:1389–96.
27. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, Gastaut JA, Pende D, Olive D, Moretta A. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. *Blood* 2002;**99**:3661–7.
28. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, Costello RT. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. *Blood* 2007;**109**:323–30.

© 2008 Kanazawa University

From www.bloodjournal.org at KANAZAWA UNIVERSITY on September 5, 2008. For personal use only.

blood

2008 112: 2160-2162
Prepublished online Jul 2, 2008;
doi:10.1182/blood-2008-02-141325

Expansion of donor-derived hematopoietic stem cells with PIGA mutation associated with late graft failure after allogeneic stem cell transplantation

Kanako Mochizuki, Chiharu Sugimori, Zhirong Qi, Xuzhang Lu, Akiyoshi Takami, Ken Ishiyama, Yukio Kondo, Hirohito Yamazaki, Hirokazu Okumura and Shinji Nakao

Updated information and services can be found at:
http://bloodjournal.hematologylibrary.org/cgi/content/full/112/5/2160

Articles on similar topics may be found in the following *Blood* collections:
Transplantation (1296 articles)
Brief Reports (1069 articles)
Clinical Trials and Observations (2413 articles)
Hematopoiesis and Stem Cells (2395 articles)
Immunobiology (3550 articles)
Red Cells (1141 articles)

Information about reproducing this article in parts or in its entirety may be found online at:
http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests

Information about ordering reprints may be found online at:
http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints

Information about subscriptions and ASH membership may be found online at:
http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published semimonthly by the American Society of Hematology, 1900 M St, NW, Suite 200, Washington DC 20036.
Copyright 2007 by The American Society of Hematology; all rights reserved.

From www.bloodjournal.org at KANAZAWA UNIVERSITY on September 5, 2008. For personal use only.

Brief report

Expansion of donor-derived hematopoietic stem cells with *PIGA* mutation associated with late graft failure after allogeneic stem cell transplantation

*Kanako Mochizuki,[1] *Chiharu Sugimori,[1] Zhirong Qi,[1] Xuzhang Lu,[1] Akiyoshi Takami,[1] Ken Ishiyama,[1] Yukio Kondo,[1] Hirohito Yamazaki,[1] Hirokazu Okumura,[1] and Shinji Nakao[1]

[1]Cellular Transplantation Biology, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan

A small population of $CD55^-CD59^-$ blood cells was detected in a patient who developed donor-type late graft failure after allogeneic stem cell transplantation (SCT) for treatment of aplastic anemia (AA). Chimerism and *PIGA* gene analyses showed the paroxysmal nocturnal hemoglobinuria (PNH)–type granulocytes to be of a donor-derived stem cell with a thymine insertion in *PIGA* exon 2. A sensitive mutation-specific polymerase chain reaction (PCR)–based analysis detected the mutation exclusively in DNA derived from the donor bone marrow (BM) cells. The patient responded to immunosuppressive therapy and achieved transfusion independence. The small population of PNH-type cells was undetectable in any of the 50 SCT recipients showing stable engraftment. The de novo development of donor cell–derived AA with a small population of PNH-type cells in this patient supports the concept that glycosyl phosphatidylinositol–anchored protein–deficient stem cells have a survival advantage in the setting of immune-mediated BM injury. (Blood. 2008;112:2160-2162)

Introduction

Although small populations of $CD55^-CD59^-$ blood cells are often detectable in patients with aplastic anemia (AA), it remains unclear how such paroxysmal nocturnal hemoglobinuria (PNH)-type cells arise.[1] We recently encountered a patient with immune-mediated late graft failure (LGF) following allogeneic stem cell transplantation (SCT) for treatment of AA. Analyses of the patient's peripheral blood (PB) and bone marrow (BM) showed hematopoietic stem cells (HSCs) of donor origin with mutant *PIGA*, supporting the concept that glycosyl phosphatidylinositol–anchored protein (GPI-AP)–deficient stem cells have a survival advantage in the setting of immune mediated BM injury.

Methods

Patients

A 59-year-old man underwent allogeneic PBSCT from a human leukocyte antigen (HLA)–matched sibling donor after conditioning with fludarabin (120 mg/m^2), cyclophosphamide (1200 mg/m^2), and antithymocyte globulin (60 mg/kg) for treatment of very severe AA in April 2002 (Table 1) and achieved complete donor chimerism with normal blood cell counts. In January 2006, he developed pancytopenia and was diagnosed as having LGF without residual recipient cells. The patient underwent a second PBSCT from the original donor without preconditioning on February 8, 2006. Pancytopenia resolved completely by day 16 after PBSCT. However, at approximately day 60, the blood counts decreased gradually, and the patient became transfusion-dependent. On day 196 after the second PBSCT, the white blood cell (WBC) count was 5.3×10^9/L with 17% neutrophils, the hemoglobin concentration was 75 g/L, and the platelet count was 22×10^9/L. Treatment with horse antithymocyte globulin (ATG) and cyclosporine was started on day 205 after the second PBSCT. Transfusions were terminated after 88 days of the immunosuppressive therapy. Although the patient presently receives low-dose tacrolimus for treatment of chronic graft-versus-host disease, which developed 1 year after the second PBSCT, his pancytopenia has markedly improved as shown in Table 1. PB and BM of the patient were subjected to analyses of chimerism and flow cytometry to detect $CD55^-CD59^-$ cells and *PIGA* gene analysis.

As controls, the PB from 51 SCT recipients (48 with hematologic malignancies and 3 with AA) who achieved a complete recovery of donor-derived hematopoiesis were subjected to flow cytometric analysis for the screening of $CD55^-CD59^-$ cells. Of the 51 patients, 4 and 23, respectively, had acute graft-versus-host disease (GVHD) of grade II or higher and chronic GVHD at sampling.

BM aspirates were obtained from the patient's donor and 10 healthy individuals for *PIGA* gene analysis. Informed consent was obtained from all patients and healthy individuals in accordance with the Declaration of Helsinki for blood examination, and the experimental protocol for *PIGA* gene analysis was approved by our participating institutional ethics committee (No.157).

Detection of PNH-type cells

To detect GPI-AP deficient (GPI-AP$^-$), PNH-type cells, we performed high-sensitivity 2-color flow cytometry of granulocytes and red blood cells (RBCs), as described previously.[1] The presence of 0.003% or more $CD55^-CD59^-CD11b^+$ granulocytes and 0.005% or more $CD55^-CD59^-$glycophorin-A^+ RBCs was defined as an abnormal increase based on the results in 183 healthy individuals.[2]

Cell sorting and chimerism analysis

$CD3^+$cells were isolated from the PB mononuclear cells of the patient using magnetic-activated cell sorting (MACS) CD3 Microbeads (Miltenyi Biotec, Auburn, CA). The $CD55^-CD59^-CD11b^+$ granulocytes were separated from the $CD55^+CD59^+CD11b^+$ granulocytes with a cell sorter (JSAN; Bay Bioscience, Yokohama, Japan). More than 95% of the sorted cells were

Submitted February 21, 2008; accepted June 17, 2008. Prepublished online as *Blood* First Edition paper, July 2, 2008; DOI 10.1182/blood-2008-02-141325.

*K.M. and C.S. contributed equally to this work.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2008 by The American Society of Hematology

From www.bloodjournal.org at KANAZAWA UNIVERSITY on September 5, 2008. For personal use only.

Table 1. Hematologic parameters of donor and recipient

	Donor		Recipient			
			Before 1st SCT	Before 2nd SCT	At ATG therapy	After 20 mo of ATG therapy
Date	Apr 2002	May 2008	Apr 2002	Jan 2006	Aug 2006	Apr 2008
WBC count, × 10^9/L	7.0	5.1	1.2	1.7	5.3	4.0
Neutrophil proportions, %	77	65	0	0	17	62
RBC count, × 10^{12}/L	4.21	4.43	2.20	2.75	2.07	3.04
Reticulocytes, × 10^9/L	not tested	35	2	3	26	61
Hemoglobin, g/L	146	150	72	89	75	120
Platelet count, × 10^9/L	261	230	19	52	22	54

$CD55^-CD59^-CD11b^+$. The *D1S80* locus was amplified from DNA of different cell populations with an AmpliFLP D1S80 PCR Amplification Kit (Perkin-Elmer Cetus, Norwalk, CT).

PIGA gene analysis

The coding regions of *PIGA* were amplified by seminested PCR or nested PCR from DNA extracted from the sorted PNH-type cells using 12 primer sets[3,4] (Table S1, available on the *Blood* website; see the Supplemental Materials link at the top of the online article), and 6 ligation reactions were used to transform competent *Escherichia coli* JM109 cells (Nippon Gene, Tokyo, Japan). Five clones were selected randomly from each group of transfectants and subjected to sequencing with a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).

Amplification refractory mutation system PCR

On the basis of a mutant sequence detected in *PIGA* of the patient, a nested amplification refractory mutation system (ARMS) forward primer with a 3'-terminal nucleotide sequence complementary to the mutant sequence was prepared[5] (Table S1). To enhance the specificity, a mismatch at the penultimate nucleotide position of the mutation site was incorporated in the ARMS forward primer (P1).[6,7] P1 and a reverse primer (P3) were used to amplify a 127 bp fragment containing the mutant sequence from the exon 2 amplified product. PCR was conducted under the following conditions; denaturation for 30 seconds at 94°C, annealing for 60 seconds at 64°C and extension for 90 seconds at 72°C for 20 cycles. Another forward primer (P2), complementary to the wild-type *PIGA* sequence upstream of the mutation site, was used in combination with P3 to amplify an internal control according to the same condition of ARMS-PCR.

Results and discussion

PNH-type cells were not detected in the donor or the patient at the time of development of the first LGF, whereas 0.147% PNH-type granulocytes and 0.019% PNH-type RBCs were detected in the PB



Figure 1. Analysis of PNH-type cells after the second PBSCT. (A) High-sensitivity flow cytometry detected small populations of $CD55^-CD59^-$ cells in both granulocytes and red blood cells at the development of the second LGF as well as in those obtained 6 and 12 months later, but did not detect PNH-type cells in the donor or in the recipient before the second PBSCT. The numbers denote the proportion of PNH-type cells in $CD11b^+$ granulocytes or glycophorin A^+ RBCs. (B) *D1S80* allelic patterns of sorted $GPI\text{-}AP^-$ granulocytes, $GPI\text{-}AP^+$ granulocytes, and $CD3^+$ lymphocytes. The polymerase chain reaction (PCR) products were subjected to 8% polyacrylamide gel electrophoresis and visualized by silver staining. (C) Nucleotide sequences of *PIGA* exon 2 in DNA from PNH-type granulocytes obtained 6 and 12 months after the second PBSCT. (D) A schematic illustration for ARMS-PCR is shown. Primer positions for the first, second are shown by short arrows. A black box and adjacent lines represent exon 2 and introns, respectively. (E) Amplified products of control PCR (the upper gel) and ARMS-PCR (the lower gel) were electrophoresed in 12.5% polyacrylamide gel and visualized by the silver staining. A pMD20-T vector containing the mutated exon 2 fragment was used as a positive control for ARMS-PCR. The template DNA derives from a plasmid containing the mutated exon 2 in lane 1, donor BM in lane 2, donor PB in lane 3, recipient BM in lane 4, recipient PB in lane 5, and BM from healthy individuals in lanes 6 to 11. PCR with a 5' primer specific to the nucleotide sequence upstream of the mutated sequence amplified a 261 bp fragment from DNA of the donor and all healthy individuals.

From www.bloodjournal.org at KANAZAWA UNIVERSITY on September 5, 2008. For personal use only.

obtained at the time of development of the second LGF (Figure 1A). Similar percentages of PNH-type blood cells were detectable in the PB of the patient 6 and 14 months later. When PB from 51 SCT recipients was examined, none of the patients were found to have detectable PNH-type cells (data not shown). PNH-type blood cells were also undetectable in a donor PB sample obtained 21 months later.

The *D1S80* locus allelic pattern of the PNH-type granulocytes in the patient was compatible to that of the donor (Figure 1B). The emergence of donor-derived PNH-type cells and hematologic improvement after immunosuppressive therapy suggest that LGF arises as a result of de novo development of AA which affects the donor-derived hematopoietic stem cells (HSCs).

PIGA gene analysis of the DNA prepared from the sorted PNH-type cells of the patient obtained at the development of LGF and 6 months later showed an insertion of thymine at position 593 (codon 198) in 3 of 5 clones and 5 of 5 clones examined, respectively (Figure 1C). Mutations in other exons were not identified. The presence of a single *PIGA* mutation in PNH-type granulocytes and its persistence over 6 months suggest that these PNH-type cells are derived from a mutant HSC rather than from a committed granulocyte progenitor cell. Moreover, an ARMS-PCR with a 5′ primer specific to the mutated sequence amplified a 127 bp fragment from DNA of the donor BM as well as of the recipient BM and PB while it failed to amplify the same fragment in donor PB and in BM of all 10 healthy individuals (Figure 1D).

These experiments demonstrate that *PIGA*-mutant HSCs were present in the BM of the donor in a dormant state and were transplanted into the recipient and provide, for the first time, in vivo evidence that *PIGA* mutant, GPI-AP–deficient HSCs have a survival advantage in the setting of immune mediated BM injury. Similarly, relative resistance to immune injury likely accounts for the high incidence of PNH observed in association with acquired AA.

Acknowledgments

We thank Ms Shizuka Yasue, Ms Megumi Yoshii, and Ms Rie Oumi for their excellent technical assistance. We also thank Dr Charles Parker for his critical reading of this manuscript.

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No.15390298), a grant from the Ministry of Health, Labour and Welfare of Japan, and a grant from the Japan Intractable Diseases Research Foundation.

Authorship

Contribution: K.M. and C.S. participated in designing and performing the research. Z.Q. and X.L. performed experiments. K.M., C.S., and S.N. wrote the paper. C.S., A.T., K.I., Y.K., H.Y., and H.O. provided patient care. All authors have approved the final version of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Shinji Nakao, Cellular Transplantation Biology, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan; e-mail: snakao@med3.m.kanazawa-u.ac.jp.

References

1. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308-1314.
2. Sugimori C, Yamazaki H, Feng X, et al. Roles of DRB1 *1501 and DRB1 *1502 in the pathogenesis of aplastic anemia. Exp Hematol. 2007;35:13-20.
3. Kai T, Shichishima T, Noji H, et al. Phenotypes and phosphatidylinositol glycan-class A gene abnormalities during cell differentiation and maturation from precursor cells to mature granulocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2002;100:3812-3818.
4. Mortazavi Y, Merk B, McIntosh J, et al. The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot. Blood. 2003;101:2833-2841.
5. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17:2503-2516.
6. Dang RK, Anthony RS, Craig JI, Leonard RC, Parker AC. Limitations of the use of single base changes in the p53 gene to detect minimal residual disease of breast cancer. Mol Pathol. 2002;55:177-181.
7. Bai RK, Wong LJ. Detection and quantification of heteroplasmic mutant mitochondrial DNA by real-time amplification refractory mutation system quantitative PCR analysis: a single-step approach. Clin Chem. 2004;50:996-1001.

Anti-Moesin Antibodies in the Serum of Patients with Aplastic Anemia Stimulate Peripheral Blood Mononuclear Cells to Secrete TNF-α and IFN-γ[1]

Hiroyuki Takamatsu,[2*†] J. Luis Espinoza,[2*] Xuzhang Lu,[*] Zhirong Qi,[*] Katsuya Okawa,[‡] and Shinji Nakao[3*]

Moesin is an intracellular protein that links the cell membrane and cytoskeleton, while also mediating the formation of microtubules and cell adhesion sites as well as ruffling of the cell membrane. To determine the roles of anti-moesin Abs derived from the serum of patients with aplastic anemia (AA) in the pathophysiology of bone marrow failure, we studied the expression of moesin on various blood cells and the effects of anti-moesin Abs on the moesin-expressing cells. The proteins recognized by anti-moesin mAbs were detectable on the surface of T cells, NK cells, and monocytes from healthy individuals as well as on THP-1 cells. The peptide mass fingerprinting of the THP-1 cell surface protein and the knock-down experiments using short hairpin RNA proved that the protein is moesin itself. Both the anti-moesin mAbs and the anti-moesin polyclonal Abs purified from the AA patients' sera stimulated THP-1 cells and the PBMCs of healthy individuals and AA patients to secrete 60–80% as much TNF-α as did LPS 100 ng/ml. Although the polyclonal Abs induced IFN-γ secretion from the PBMCs of healthy individuals only when the PBMCs were prestimulated by anti-CD3 mAbs, the anti-moesin Abs were capable of inducing IFN-γ secretion from the PBMCs of AA patients by themselves. Anti-moesin Abs may therefore indirectly contribute to the suppression of hematopoiesis in AA patients by inducing myelosuppressive cytokines from immunocompetent cells. *The Journal of Immunology,* **2009, 182: 703–710.**

Acquired aplastic anemia (AA)[4] is a syndrome characterized by pancytopenia and bone marrow (BM) hypoplasia (1). The T cell-mediated suppression of hematopoiesis is considered to be the most important mechanism responsible for the development of this syndrome because approximately 70% of AA patients respond to immunosuppressive therapy, such as antithymocyte globulin and cyclosporine (2, 3). In addition to a large body of evidence for T cell involvement in the pathogenesis of AA (4–7), recent studies have revealed the presence of Abs specific to self-Ags in the serum of AA patients (8–11). Although some of these Abs are directed toward Ags that are abundant in hematopoietic cells (e.g., kinectin (Ref. 8) and DRS-1 (Ref. 9)), their roles in the pathophysiology of AA are unclear.

Of the various autoAbs detected in the autoimmune diseases, some are known to exhibit stimulatory effects on the target cells rather than inhibitory effects, such as anti-thyroglobulin Abs in Basedow's disease (12) and anti-desmoglein Abs in pemphigus vulgaris (12, 13). The autoAbs specific to platelet-derived growth factor receptors in patients with scleroderma and those with extensive chronic graft-vs-host diseases trigger an intracellular loop, involving Ha-Ras-ERK 1 and 2 (ERK 1/2)-reactive oxygen species (Ha-Ras-ERK 1/2-ROS), and augment collagen gene expression as well as myofibroblast phenotype conversion of normal human primary fibroblasts (14, 15). The anti-proteinase 3 Abs detected in Wegener's granuloma stimulate monocytes through the binding of cell surface proteinase 3 to secrete IL-8 (16). The autoAbs detected in AA patients may also be involved in the pathophysiology of BM failure by way of other mechanisms than the direct toxicity against the hematopoietic cells, though there has been no evidence for such functional autoAbs in AA patients.

We previously demonstrated that Abs specific to moesin, a membrane-cytoskeleton linker protein in the cytoplasm, were detectable in approximately 40% of AA patients (11). Moesin is an intracellular protein that links the cell membrane and cytoskeleton, and mediates the formation of microtubules and cell adhesion sites as well as ruffling of the cell membrane (17). On the other hand, some reports have identified molecules that were recognized by anti-moesin mAbs on the surface of blood cells such as T cells and macrophages (18, 19). Because these immune cells are an important source of myelosuppressive cytokines such as TNF-α and IFN-γ, it is conceivable that anti-moesin Abs in AA patients may bind such moesin-like molecules on these immune cells and affect the cytokine secretion from these cells.

To test these hypotheses, we studied the expression of moesin on blood cells and the effects of anti-moesin Abs on the moesin-expressing

*Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, and †Internal Medicine, NTT WEST Kanazawa Hospital, Kanazawa, Ishikawa, and ‡Biomolecular Characterization Unit, Frontier Technology Center, Kyoto University Graduate School of Medicine, Kyoto, Japan

Received for publication August 28, 2008. Accepted for publication October 22, 2008.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[1] This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Technology, Sports and Culture of Japan (KAKENHI No. 19659243) and grants from the Research Committee for Idiopathic Hematopoietic Disorders, the Ministry of Health, Labor, and Welfare, Japan.

[2] H.T. and J.L.E. contributed equally to this work.

[3] Address correspondence and reprint requests to Dr. Shinji Nakao, Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa 920-8641, Japan. E-mail address: snakao@med3.m.kanazawa-u.ac.jp

[4] Abbreviations used in this paper: AA, aplastic anemia; BM, bone marrow; pAb, polyclonal Ab; PB, peripheral blood.

Copyright © 2008 by The American Association of Immunologists, Inc. 0022-1767/08/$2.00

cells. The present study revealed a novel function of autoAbs, which may contribute to the pathophysiology of BM failure.

Materials and Methods

Study subjects (patients)

Sera were obtained from 19 patients with AA and 4 healthy individuals. BM plasma was obtained from five patients with AA and three healthy individuals. All AA patients had severe AA and were positive for anti-moesin Abs. The samples were cryopreserved at −80°C until use. Peripheral blood (PB) was obtained from 7 patients with AA and 10 healthy individuals and BM was aspirated from 3 healthy individuals. The PBMCs were isolated using lymphoprep (Nycomed). All patients and healthy volunteers provided an informed consent before sampling according to the Declaration of Helsinki. This study was approved by the human research committee of Kanazawa University Graduate School of Medical Science.

Cell lines

Molt-4, THP-1, U937, K562, Daudi, and Jurkat cell lines were purchased from the Health Science Research Resources Bank. A megakaryoblastic leukemia cell line UT-7, a myeloid leukemia cell lines OUN-1, and a myelodysplastic syndrome cell line TF-1 were provided by Dr. N. Komatsu of Jichi Medical School, Dr. M.Yasukawa of Ehime University, and Dr. S. Ogawa of the University of Tokyo, respectively.

Purification of anti-moesin Abs in the sera of patients with AA

The anti-moesin polyclonal Abs (pAbs) were purified from the patients' serum with affinity chromatography using a protein G column (mAb Trap kit, no. 17-1128-0; GE Healthcare) and recombinant moesin protein (11) fixed on an agarose-gel column (1 ml, HiTrap NHS-activated HP, no. 17-0716-01; GE Healthcare) according to the manufacturer's instruction. In brief, 20 ml of serum from AA patients was applied to the Protein G column. After washing with the binding buffer, the whole IgG was eluted with the elution buffer and neutralized with the neutralizing buffer. The purified IgG was then applied to the recombinant moesin-fixed affinity chromatography column. After washing with the binding buffer (75 mM sodium phosphate (pH 8.0)), anti-moesin pAbs were eluted with the elution buffer (100 mM glycine-HCl and 500 mM NaCl (pH 2.7)). The purified anti-moesin pAbs were dialyzed in PBS at 4°C overnight using a spectra/Por Float-A-Lyzer column (Spectrum Laboratories; no. 235118). The purity of the isolated anti-moesin pAbs was confirmed by PAGE followed by Coomassie Brilliant Blue staining.

Flow cytometry

Mouse anti-moesin mAb (clone 38/87; Neomarkers) which was labeled with FITC (Immuno-Biological Laboratories) was used in combination with mAbs specific to CD3-PE (BD Pharmingen; no. 555333), CD19-PE (BD Pharmingen; No. 555413), CD4-PE (BD Pharmingen; No. 347327), CD-8-PE (BD Pharmingen; no. 555367), CD14-PE (BD Pharmingen; No. 555398), CD11b-PE (BD Pharmingen; No. 555388), CD34-PE (BD Pharmingen; no. 348057), and CD3-Cy-Chrome (BD Pharmingen; no. 555334). Isotype-matched control mAbs (BD Pharmingen) were used as negative controls. For the detection of moesin-like molecules on leukocytes and leukemia cell lines, 1 μl of anti-moesin mAbs and 2 μl of PE-labeled mAbs were added to 50 μl of cell suspension containing 1×10^6 cells and the suspension was incubated on ice for 30 min. For the detection of moesin-like molecules by pAbs, 1×10^6 THP-1 cells were washed twice with PBS containing 1% BSA (Sigma-Aldrich; no. A8022) and resuspended in 200 μl of a PBS containing 2% FCS, 2% goat serum, and 2% BSA. The cell suspension was incubated for 30 min at 4°C. Then, 5 μg/ml anti-moesin pAbs or isotype control human IgG pAbs isolated from healthy individuals were added to the cell suspension and incubated for 1 h at 4°C. The cells were washed twice with PBS containing 1% BSA followed by incubation with a secondary Ab (goat anti-human IgG FITC-labeled Ab; Sigma-Aldrich; no. F5512) diluted 1/100 in PBS containing 2% goat serum and were incubated at 4°C for 30 min. Finally, the cells were washed twice with PBS containing 1% BSA and subjected to flow cytometry.

Stimulation of THP-1 cells with PMA/LPS

THP-1 cells (10^6) were suspended in 2 ml of RPMI 1640 containing 10% FCS and 20 ng/ml PMA (Wako Chemicals; no. 545-00261) and incubated for 24 h at 37°C in a CO_2 incubator. A total of 10 ng/ml LPS (Sigma-Aldrich; no. L2880) was added to the cell suspension and further incubated for 20 h. The cultured cells were analyzed for the expression of moesin-like molecules by flow cytometry using anti-moesin mAbs (clone 38/87; Neomarkers).

Isolation of monocytes and T cells

Monocytes were isolated by plastic adherence as previously described (20). In brief, 5×10^6 PBMCs/well were distributed into 12-well plates (Corning) and allowed to adhere in a 5% CO_2 incubator at 37° for 2 h in RPMI 1640 supplemented with 10% (v/v) heat-inactivated FCS, 100 U/ml penicillin - 0.1 mg/ml streptomycin (Invitrogen; No.15140-148) and 10 μg/ml polymyxin B (Aerosporin) (Sigma-Aldrich; no. 194538). Nonadherent cells were removed and the remaining adherent cells on the plates were used as monocytes. T cells were purified by negative selection using the Human T Cell Enrichment Columns (R&D Systems; no. HTCC-500) following the manufacturer instructions. The purity of enriched T cells and monocytes was approximately 90% as determined by flow cytometry using anti-CD3-PE and anti-CD-14-PE mAbs, respectively.

Stimulation of THP-1 cells, PBMCs, monocytes, and T cells with anti-moesin Abs

THP-1 cells, PBMCs, monocytes, or T cells were suspended in RPMI 1640 supplemented with 10% (v/v) heat-inactivated FCS. Polymyxin B (Aerosporin) (Sigma-Aldrich; no. 194538) was added at 10 μg/ml to eliminate any contaminating endotoxin. The endotoxin concentration in the pAbs and the reagents used for culture was <10 pg/ml as demonstrated by chromogenic *Limulus* amebocyte lysate assay (Seikagaku). The cells (5×10^5) were incubated for 48 h in the presence of 5 μg/ml of anti-moesin mouse mAbs (clone 38/87, IgG1; Neomarkers) or 5–10 μg/ml of pAbs isolated from the serum of AA patients as described above. Mouse mAbs (Coulter Clone; IgG1, no. 6602872) and control human IgG pAbs isolated from healthy individuals were used as negative controls. This Ab concentration was selected based on an estimated concentration of anti-moesin pAbs in the serum of an AA patient. For prestimulation of PBMCs to induce IFN-γ secretion, the cells were incubated for 1 h in the presence of 100 ng/ml of anti-CD3 mAbs (Clone OKT3) (eBioscience; functional grade no. 16-0037). For costimulation of isolated T cells to induce IFN-γ secretion, the cells were cultured for 48 h on a 48-well tissue culture plate that was coated with 100 ng/ml of anti-CD3 mAbs (clone OKT3) (eBioscience; functional grade no. 16-0037) overnight at 4°C and washed. Then, 100 ng/ml LPS or 10 μg/ml PHA (Sigma-Aldrich; no. L4144) was included instead of anti-moesin Abs as the positive controls for the induction of TNF-α or IFN-γ secretion, respectively, and control human IgG pAbs isolated from healthy individuals were added as a negative control.

Western blotting

Western blotting was performed using THP-1 cell lysates. The specific bands were visualized by anti-moesin mAbs, pAbs from AA patients, or control human IgG pAbs from healthy individuals as described in a previous report (11). The expression levels of α-tubulin were determined as an internal control using Western blotting with anti-α-tubulin mAbs (Sigma-Aldrich; no. T 5168).

Isolation of proteins on the surface of THP-1 cells

The THP-1 cells were treated with sulfo-NHS-SS-biotin, and the cell surface proteins were isolated with avidin-fixed columns according to the manufacturer's instructions (Pierce). Thereafter, 1×10^7 cells were washed twice with 8 ml of ice-cold PBS. The cells were suspended in 10 ml PBS containing 2.5 mg sulfo-NHS-SS-Biotin and incubated for 30 min at 4°C. Then, 500 μl of quenching solution was added to the cell suspension and the cells were washed with 10 ml TBS twice. The cell pellet was lysed in 500 μl of lysis buffer containing 60 μl of preotease inhibitor cocktail (Sigma-Aldrich; no. P-8340) and then disrupted by sonication. The biotin-labeled membrane proteins were isolated by an immobilized NeutrAvidin Gel column. The isolated membrane proteins were subjected to Western blotting and peptide mass fingerprinting.

Peptide mass fingerprinting

Mass spectrometric identification of 80- and 75-kDa proteins on the surface of the THP-1 cells was performed as previously described (21). In brief, the proteins fractionated by SDS-PAGE were visualized by Coomassie Brilliant Blue staining and the 80- and 75-kDa bands were excised from gels, followed by in-gel digestions with trypsin (Promega) in a buffer containing 50 mM ammonium bicarbonate (pH 8.0) and 2% acetonitrile overnight at 37°C. Molecular mass analyses of the tryptic



FIGURE 1. Expression of moesin-like molecules on the surface of various blood cells. PB lymphocytes, granulocytes, and monocytes, as well as BM mononuclear cells, of a healthy individual and a patient with AA were analyzed by flow cytometry. The gate was set up for lymphocytes (*a–d*), CD3⁻ lymphocytes (*e*), granulocytes (*g* and *j*), and monocytes (*h* and *k*) derived from a healthy individual and monocytes (*i* and *l*) derived from an AA patient. BM mononuclear cells (*f*) of a healthy individual were included in the analysis. One representative result of three experiments is shown.

peptides were performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using an ultraflex TOF/TOF (Bruker Daltonics). The proteins were identified by comparisons between the molecular weights determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and the theoretical peptide masses of proteins registered in NCBInr.